Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Pronai, W; Neyer, U; Barnas, U; Wieser, C; Jaeger, C; Dekic, D; Hemetsberger, M; Rosenkranz, AR.
Darbepoetin alfa once every 2 weeks effectively maintained hemoglobin in dialysis patients in an observational study: Austrian cohort of ALTERNATE.
Wien Med Wochenschr. 2014; 164(5-6): 109-119. Doi: 10.1007/s10354-013-0256-7
PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Rosenkranz Alexander
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: ALTERNATE is an international observational study evaluating biweekly darbepoetin alfa (DA) in adult dialysis patients in clinical practice. Austrian ALTERNATE results are presented here (n = 505). The follow-up study ALTERNATE follow-up (AFU) followed Austrian ALTERNATE patients for an additional 12 months (n = 135). Data were collected 6 months before and 12 months after conversion to biweekly dosing and during 12 months of follow-up. The primary measures were hemoglobin concentration 12 months after conversion and at the end of AFU, respectively. Mean (95 % CI) hemoglobin (g/dL) was 11.87 (11.75-11.99) at conversion, 11.71 (11.58-11.83) at month 12, and 11.66 (11.45-11.86) at end of AFU. Geometric mean (95 % CI) weekly dose (μg/wk) was 32.97 (30.80-35.30) at conversion, 29.90 (26.71-33.46) 12 months after conversion, and 24.38 (18.40-30.35) at end of AFU. The studies show that hemoglobin and dose could be effectively maintained over an extended period of time after conversion from higher frequency erythropoiesis-stimulating agents to biweekly DA.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Aged -; Cohort Studies -; Dose-Response Relationship, Drug -; Drug Administration Schedule -; Erythropoietin - analogs & derivatives Erythropoietin - therapeutic use; Female -; Follow-Up Studies -; Hematinics - therapeutic use; Hemoglobinometry -; Humans -; Kidney Failure, Chronic - blood Kidney Failure, Chronic - therapy; Long-Term Care -; Male -; Middle Aged -; Peritoneal Dialysis -; Renal Dialysis -